Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpelisib + ganitumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Alpelisib + ganitumab is an investigational **combination therapy** composed of **alpelisib**, a selective inhibitor of the phosphatidylinositol 3-kinase catalytic subunit alpha (PI3Kα), and **ganitumab**, a fully human monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). - **Alpelisib** inhibits the PI3K/AKT/mTOR pathway, commonly activated in cancer through **PIK3CA mutations**, to decrease tumor growth and proliferation. - **Ganitumab** binds and blocks IGF-1R, inhibiting receptor-mediated signaling involved in cell survival and proliferation. This combination is under investigation for cancer indications where these pathways are implicated in disease progression or drug resistance.
- Other names
- alpelisib + ganitumab
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on alpelisib + ganitumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpelisib + ganitumab.